Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations
Biogen made just $300,000 from the Alzheimer’s disease treatment Aduhelm in the first full quarter since its approval.
Biogen made just $300,000 from the Alzheimer’s disease treatment Aduhelm in the first full quarter since its approval.
Explore the impact of severe migraine and discuss the critical need for conversation between health care providers and patients navigating treatment options during this virtual…
Hospitals and some insurers face big hits to their finances if Republicans eliminate or scale back parts of the Affordable Care Act
Amid alarm over how a Trump administration, including RFK Jr., might interfere with public health, a Kennedy relative is expressing concern.
Expanding global access to infectious disease medicines Ahmed Ahmed blends public policy with medicine to learn about the healthcare workforce. Read his story.
Today’s health news includes a natural experiment: The health outcomes of babies born before and after World War II-era sugar ration rules.
Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.
A new generation of young scientists trained in top CRISPR labs are striking out on their own.
In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target another protein thought to play a role…
People in science are increasingly concerned about how wading into partisan politics may further erode trust in their field.
Opinion: A new study finds that doctors really do judge patients negatively when they share false beliefs.